People · Operator
Named in public records as an officer, director or promoter · active 2008–2022 · Biotechnology, Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neurona Therapeutics, Inc | — | Biotechnology | Series D+ | $347.5M | $874.2M | 2014 |
| Ngm Biopharmaceuticals Inc | — | Biotechnology | Series D+ | $341.3M | $4.4B | 2008 |
| RAPT Therapeutics, Inc. | — | Biotechnology | Series D+ | $317.0M | $1.4B | 2016 |
| Constellation Pharmaceuticals Inc | — | Biotechnology | Series C | $286.4M | $2.7B | 2010 |
| Hexagon Bio Inc. | — | Biotechnology | Series C | $148.6M | $1.2B | 2021 |
| Nurix Therapeutics, Inc. | — | Pharma | Series D+ | $144.7M | $4.2B | 2012 |
| A2 Biotherapeutics, Inc. | — | Biotechnology | Series C | $143.1M | $1.2B | 2020 |
| Igenica Inc | — | Pharmaceuticals | Series B | $70.0M | $76.5M | 2010 |
| Surrozen, Inc. | — | Biotechnology | Series C | $50.0M | $2.0B | 2020 |
| Peloton Therapeutics, Inc. | — | Biotechnology | Series A | $13.7M | $423.0M | 2011 |
David Goeddel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Goeddel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tim Kutzkey | 3 | 7 |
| William J. Rieflin | 2 | 4 |
| Peter Svennilson | 2 | 4 |
| Robert Tjian | 2 | 3 |
| David V. Goeddel | 2 | 2 |
| Mark Goldsmith | 2 | 2 |
| Michael Brown | 1 | 34 |
| Carl Gordon | 1 | 24 |
| LEON CHEN | 1 | 15 |
| Beth Seidenberg | 1 | 15 |
| Alex Kolicich | 1 | 8 |
| Helen S. Kim | 1 | 6 |
| Anthony Evnin | 1 | 6 |
| John Creecy | 1 | 5 |
| Craig Parker | 1 | 5 |
| Leo - Guthart | 1 | 4 |
| Keith Dionne | 1 | 3 |
| Erica Whittaker | 1 | 3 |
| John Josey | 1 | 3 |
| John Diekman | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.